Biostar

BioStar Capital Closes Fund V at $130.3 Million, Surpassing Previous Funds

Retrieved on: 
Wednesday, December 6, 2023
Technology, Medical Devices, Finance, Health Technology, Professional Services, Cardiology, Health, Robotics, General Health, Artery, Tricuspid valve, Investment, Disease, Elective surgery, MMI, Cardiovascular disease, CE marking, Biostar, Instrument, AVS, Cleveland Clinic, Optimism, Pharmaceutical industry

BioStar Capital , a strategic venture capital firm focusing on transformative medical technologies primarily in the fields of cardiovascular disease, orthopedics, and robotics, has announced it has closed its fifth fund at $130.3 million, more than its three previous funds combined.

Key Points: 
  • BioStar Capital , a strategic venture capital firm focusing on transformative medical technologies primarily in the fields of cardiovascular disease, orthopedics, and robotics, has announced it has closed its fifth fund at $130.3 million, more than its three previous funds combined.
  • BioStar expects to invest in 8-10 additional companies over the next five years.
  • In a time of declining investments in venture capital, BioStar’s closing overcame current environmental challenges, demonstrating investor confidence in the firm’s unique model leveraging physician, as well as financial and operational expertise in today’s dynamic healthcare environment.
  • While other venture capital firms are shifting their focus to areas such as cardiovascular medical devices, few have the decades of experience and clinical expertise that BioStar offers through its team of Medical Venture Partners (“MVPs”) and network of physician investors.

SomaLogic and Korea’s DNA Link partner to bring the 7,000-plex SomaScan® platform to the fast-growing Asia-Pacific proteomics market

Retrieved on: 
Tuesday, September 19, 2023
DNA, Partnership, Drug development, Therapy, Biostar, Research, Genomics, Proteomics, Medicine, Health, SomaLogic, Vaccine

DNA Link will be the first SomaLogic authorized site in Korea.

Key Points: 
  • DNA Link will be the first SomaLogic authorized site in Korea.
  • “Over the past 20 years, DNA Link has cultivated a reputation for generating and interpreting high-quality genomic data,” said Chief Executive Officer of DNA Link, Lee Jong-eun.
  • DNA Link has been conducting genomics research from its labs for more than two decades with a focus on genetic epidemiology, drug development and personalized medicine.
  • DNA Link joins Biostar in China , Molecular Genomics in Singapore and FonesLife in Japan as SomaLogic authorized sites in the APAC region.

Introducing BIOSTAR® cutting-edge Conventional TBNA (cTBNA) and Endobronchial ultrasound (EBUS) TBNA (EBUS-TBNA) needle: Revolutionizing Minimally Invasive Diagnostic techniques

Retrieved on: 
Friday, September 8, 2023
Collection, Biostar, Lung cancer, TBNA, Doctor of Philosophy, US, EBUS, SAN, Diagnosis, Health, Medical device, Medical imaging, Microscope

Built with a focus on enhancing patient care and clinical outcomes, this state-of-the-art needle seamlessly integrates with endobronchial ultrasound bronchoscopy (EBUS) procedures.

Key Points: 
  • Built with a focus on enhancing patient care and clinical outcomes, this state-of-the-art needle seamlessly integrates with endobronchial ultrasound bronchoscopy (EBUS) procedures.
  • The BioStar® is intended to be used for both Conventional TBNA (cTBNA) and endobronchial ultrasound (EBUS) TBNA (EBUS-TBNA) diagnostic techniques.
  • Streamlined Workflow: With a user-friendly interface and intuitive setup, the BioStar® TBNA Needle streamlines procedural workflow, saving valuable time in busy clinical settings.
  • The BioStar® TBNA Needle is now available for medical practitioners in Europe and the rest of the world except USA*, seeking to elevate their diagnostic capabilities.

Introducing BIOSTAR® cutting-edge Conventional TBNA (cTBNA) and Endobronchial ultrasound (EBUS) TBNA (EBUS-TBNA) needle: Revolutionizing Minimally Invasive Diagnostic techniques

Retrieved on: 
Friday, September 8, 2023
Collection, Biostar, Lung cancer, TBNA, Doctor of Philosophy, US, EBUS, SAN, Diagnosis, Health, Medical device, Medical imaging, Microscope

Built with a focus on enhancing patient care and clinical outcomes, this state-of-the-art needle seamlessly integrates with endobronchial ultrasound bronchoscopy (EBUS) procedures.

Key Points: 
  • Built with a focus on enhancing patient care and clinical outcomes, this state-of-the-art needle seamlessly integrates with endobronchial ultrasound bronchoscopy (EBUS) procedures.
  • The BioStar® is intended to be used for both Conventional TBNA (cTBNA) and endobronchial ultrasound (EBUS) TBNA (EBUS-TBNA) diagnostic techniques.
  • Streamlined Workflow: With a user-friendly interface and intuitive setup, the BioStar® TBNA Needle streamlines procedural workflow, saving valuable time in busy clinical settings.
  • The BioStar® TBNA Needle is now available for medical practitioners in Europe and the rest of the world except USA*, seeking to elevate their diagnostic capabilities.

FDA Approved Utidelone Injectable (UTD1) Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer

Retrieved on: 
Thursday, June 15, 2023
Docetaxel, DCR, Biostar, Clinical trial, OS, Lung cancer, NSCLC, Immunotherapy, PFS, Drug resistance, Patient, SAN, FDA, IND, Synthetic biology, ORR, Taxane, Pharmaceutical industry

Dr. Li Tang, Chairman of Biostar Pharma commented: "This is an important milestone for global development of utidelone injectable -- an innovative anti-cancer drug and new generation epothilone analogue. We are fully committed to advancing this pivotal multi-national study and also willing to partner with global pharmaceutical companies to bring this product to market around the world to benefit more patients".

Key Points: 
  • Designated as BG01-2202, this trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable (UTD1) versus docetaxel.
  • The study is going to be conducted at about 50 sites in about 10 countries and regions across US, Europe and Asia -Pacific.
  • Dr. Li Tang, Chairman of Biostar Pharma commented: "This is an important milestone for global development of utidelone injectable -- an innovative anti-cancer drug and new generation epothilone analogue.
  • NSCLC accounts for about 85% of lung cancer cases [2,3] and more than 75% of patients with lung cancer are diagnosed with locally advanced or stage IV disease [4].

SomaLogic expands into China with groundbreaking Biostar Technology Limited Partnership

Retrieved on: 
Wednesday, May 10, 2023
Partnership, Hepatology, Genomics, Health care, Biostar, Cancer, Proteomics, SomaLogic, Medical imaging

SHANGHAI and BOULDER, Colo., May 10, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, announced today that Biostar Technology Limited will be the company’s first authorized site in China to offer the 7,000-plex SomaScan® Assay and provide SomaScan data to their customers.

Key Points: 
  • SHANGHAI and BOULDER, Colo., May 10, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, announced today that Biostar Technology Limited will be the company’s first authorized site in China to offer the 7,000-plex SomaScan® Assay and provide SomaScan data to their customers.
  • “We are delighted to be partnering with SomaLogic to expand the company’s global reach in Asia by providing their next-generation proteomics offering and establishing the first SomaLogic authorized site in Shanghai,” said founding Chief Executive Officer of Biostar and AccuraMed Steven Qiu.
  • Biostar will now be the first in the nation to offer SomaLogic’s proteomics technology.
  • “China is an exciting market for proteomics with tremendous untapped growth potential for SomaLogic,” said SomaLogic Chief Executive Officer Adam Taich.

AMD Unveils World’s Most Advanced Gaming Graphics Cards, Built on Groundbreaking AMD RDNA 3 Architecture with Chiplet Design

Retrieved on: 
Thursday, November 3, 2022
ROG, Private Securities Litigation Reform Act, HEVC, Unreal, GB, Intel, Cyberpunk 2077, Software, U.S. Securities and Exchange Commission, HDMI, HDMI Licensing, Technology, Blog, Biostar, XTX, AMD, Maury Yeston, LLC, Video, Intellectual property, Memory, SOC, GPU, XFX, Forward-looking statement, Tai chi, RX, DisplayPort, FFmpeg, AV1, Efficiency, RDNA, Government, FreeSync, Dying Light 2, TBP, FSR, COVID-19, Corruption, Video Electronics Standards Association, DDR5, Review, PowerColor, ASRock, Information, Advanced Micro Devices, ASUS, Ryzen, MSI, Microsoft, VP9, AM5, XT, RDNA 2, Investment, Bfloat16 floating-point format, BRP, CPU, FS2, Safe harbor, NASDAQ, Name, Fortnite, FPS, WI-FI, Cryptocurrency, Video game console, Sapphire, Gigabyte, Siempre Estoy Pensando en Ti, Radeon, Xilinx

LAS VEGAS, Nov. 03, 2022 (GLOBE NEWSWIRE) -- AMD (NASDAQ: AMD) today unveiled new graphics cards built on the next-generation high-performance, energy-efficient AMD RDNA™ 3 architecture – the AMD Radeon™ RX 7900 XTX and Radeon RX 7900 XT graphics cards. Following on the highly successful AMD “Zen”-based AMD Ryzen™ chiplet processors, the new graphics cards are the world’s first gaming graphics cards to feature an advanced AMD chiplet design. They deliver exceptional performance and superb energy efficiency to power high-framerate 4K and higher resolution gaming in the most demanding titles.

Key Points: 
  • The AMD Radeon RX 7900 XTX has an SEP of $999 USD, while the AMD Radeon RX 7900 XT has an SEP of $899 USD.
  • Learn more about AMD Software: Adrenalin Edition application here
    For more than 50 years AMD has driven innovation in high-performance computing, graphics and visualization technologies.
  • For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ: AMD) website , blog , LinkedIn and Twitter pages.
  • 7RX-838 Based on AMD internal analysis, November 2022, comparing the game clock frequencies at launch of RDNA 2 vs. RDNA 3.

Medical Microinstruments Introduces Even Smaller Robotic Instruments to Address Complex Supermicrosurgery

Retrieved on: 
Wednesday, September 7, 2022
Artery, Lymphedema, CEO, Cancer, RA, DDS, Oral, Hand, Suture, Oral and maxillofacial surgery, Robotics, Supermicro, Tongue, Department, Union, Microsurgery, Vein, MD, Surgeon, Frasier, MMI, Patient, Dentistry, EU, Biostar

PISA, Italy, Sept. 7, 2022 /PRNewswire/ -- Medical Microinstruments, Inc. (MMI), a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced the launch of its new Supermicro NanoWrist® instruments for use with the Symani® Surgical System, developed specifically to address the challenges of microsurgery. The new supermicro needle holder and dilator were recently used in clinical procedures in Zürich, Florence, and Salzburg, with successful patient outcomes.

Key Points: 
  • "We've already seen the benefits of Symani and the NanoWrist instruments in improving dexterity and control," said Dr. Enzinger.
  • "The new supermicro instrument tips are even smaller and more refined, making it significantly easier to precisely connect vessels under one millimeter in diameter.
  • Medical Microinstruments, Inc. (MMI) was founded in 2015 near Pisa, Italy to enhance surgical performance through the development of a robotic system that enables surgeons to achieve better outcomes in microsurgery.
  • The Symani Surgical System combines proprietary innovations including the world's smallest wristed microinstruments as well as tremor-reducing and motion-scaling technologies.

Medical Microinstruments Introduces Even Smaller Robotic Instruments to Address Complex Supermicrosurgery

Retrieved on: 
Wednesday, September 7, 2022
Artery, Lymphedema, CEO, Cancer, RA, DDS, Oral, Hand, Suture, Oral and maxillofacial surgery, Robotics, Supermicro, Tongue, Department, Union, Microsurgery, Vein, MD, Surgeon, Frasier, MMI, Patient, Dentistry, EU, Biostar

PISA, Italy, Sept. 7, 2022 /PRNewswire/ -- Medical Microinstruments, Inc. (MMI), a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced the launch of its new Supermicro NanoWrist® instruments for use with the Symani® Surgical System, developed specifically to address the challenges of microsurgery. The new supermicro needle holder and dilator were recently used in clinical procedures in Zürich, Florence, and Salzburg, with successful patient outcomes.

Key Points: 
  • "We've already seen the benefits of Symani and the NanoWrist instruments in improving dexterity and control," said Dr. Enzinger.
  • "The new supermicro instrument tips are even smaller and more refined, making it significantly easier to precisely connect vessels under one millimeter in diameter.
  • Medical Microinstruments, Inc. (MMI) was founded in 2015 near Pisa, Italy to enhance surgical performance through the development of a robotic system that enables surgeons to achieve better outcomes in microsurgery.
  • The Symani Surgical System combines proprietary innovations including the world's smallest wristed microinstruments as well as tremor-reducing and motion-scaling technologies.

Medical Microinstruments Secures $75M to Advance Robotic Microsurgery

Retrieved on: 
Wednesday, July 20, 2022
Surgery, Medical Devices, Health, Robotics, Technology, Regulation of tobacco by the U.S. Food and Drug Administration, Instrument, Neurosurgery, Surgeon, Center, Food, Health, CEO, Research, Platform supply vessel, Trauma, Hand, Board, Therapy, Cancer, ZEUS robotic surgical system, RA, Artery, Technology, Vein, Tremor, Patient, Robotics, Center of excellence, Comau, Microsurgery, MMI, IDE, Growth, Medical device, Management, Dentistry, Biostar, MD, Atlantic Ocean

Medical Microinstruments, Inc. (MMI) , a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced it has raised $75 million in Series B financing.

Key Points: 
  • Medical Microinstruments, Inc. (MMI) , a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced it has raised $75 million in Series B financing.
  • Robotic microsurgery has enormous potential to both improve the standard of care for patients and help surgeons manage procedures that require delicate precision, said Ms. Cameron.
  • Medical Microinstruments, Inc. (MMI) was founded in 2015 near Pisa, Italy to enhance surgical performance through the development of a robotic system that enables surgeons to achieve better outcomes in microsurgery.
  • The Symani Surgical System combines proprietary innovations including the worlds smallest wristed microinstruments as well as tremor-reducing and motion-scaling technologies.